miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review.
Mol Ther Nucleic Acids
; 27: 1191-1224, 2022 Mar 08.
Article
em En
| MEDLINE
| ID: mdl-35282417
ABSTRACT
Among deregulated microRNAs (miRs) in human malignancies, miR-221 has been widely investigated for its oncogenic role and as a promising biomarker. Moreover, recent evidence suggests miR-221 as a fine-tuner of chronic liver injury and inflammation-related events. Available information also supports the potential of miR-221 silencing as promising therapeutic intervention. In this systematic review, we selected papers from the principal databases (PubMed, MedLine, Medscape, ASCO, ESMO) between January 2012 and December 2020, using the keywords "miR-221" and the specific keywords related to the most important hematologic and solid malignancies, and some non-malignant diseases, to define and characterize deregulated miR-221 as a valuable therapeutic target in the modern vision of molecular medicine. We found a major role of miR-221 in this view.
NASH; biliary tract cancer; bladder cancer; breast cancer; cancer; cervical cancer; demyelinating diseases; endometrial cancer; gastrointestinal cancer; glioblastoma; gynecological cancers; hematological diseases; hepatocellular carcinoma; lung cancer; melanoma; miR; miR therapeutics; miR-221; miR-221/222; miRs; microRNA; myeloma; neuropathy; ovarian cancer; pancreatic cancer; pharmacokinetics; prostate cancer; renal cell carcinoma; sarcomas; solid cancers; urogenital cancer
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Systematic_reviews
Idioma:
En
Revista:
Mol Ther Nucleic Acids
Ano de publicação:
2022
Tipo de documento:
Article